M. Demario

发表

Preclinical biomarkers for a cyclin-dependent kinase inhibitor translate to candidate pharmacodynamic biomarkers in phase I patients

James Rosinski, Paul Delmar, J. Rosinski, 2009, Molecular Cancer Therapeutics.

Phase I and pharmacokinetic study of the novel oral cell-cycle inhibitor Ro 31-7453 in patients with advanced solid tumors.

S. Soignet, P. Sabbatini, M. Demario, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

RG7212 Anti-TWEAK mAb Inhibits Tumor Growth through Inhibition of Tumor Cell Proliferation and Survival Signaling and by Enhancing the Host Antitumor Immune Response

J. Rosinski, H. Hilton, K. Packman, 2013, Clinical Cancer Research.

AIDS-Related Malignancies

M. Demario, D. Liebowitz, M. DeMario, 1999 .

Phase 1b study of the BET protein inhibitor RO6870810 with venetoclax and rituximab in patients with diffuse large B-cell lymphoma

J. Briones, E. González-Barca, J. Brouwer-Visser, 2021, Blood advances.

Oral chemotherapy: rationale and future directions.

M. Ratain, M. Demario, M. DeMario, 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Personalized neoantigen vaccine NEO-PV-01 with chemotherapy and anti-PD-1 as first-line treatment for non-squamous non-small cell lung cancer.

R. Govindan, Michael S. Rooney, H. Sethi, 2022, Cancer cell.

A phase 1b dose-escalation/expansion study of BET inhibitor RO6870810 in patients with advanced multiple myeloma

J. Laubach, M. Liedtke, A. Chanan-Khan, 2021, Blood Cancer Journal.

A Phase I Clinical and Pharmacokinetic Study of Ro 31-7453 Given as a 7- or 14-Day Oral Twice Daily Schedule Every 4 Weeks in Patients with Solid Tumors

R. Salazar, D. Bissett, S. Ritland, 2004, Clinical Cancer Research.

Exposure and Tumor Fn14 Expression as Determinants of Pharmacodynamics of the Anti-TWEAK Monoclonal Antibody RG7212 in Patients with Fn14-Positive Solid Tumors

J. Schellens, L. Siu, A. Hansen, 2015, Clinical Cancer Research.

A Phase I Monotherapy Study of RG7212, a First-in-Class Monoclonal Antibody Targeting TWEAK Signaling in Patients with Advanced Cancers

J. Schellens, A. Hansen, M. Demario, 2014, Clinical Cancer Research.

Cancer Therapy : Preclinical RG 7212 Anti-TWEAK mAb Inhibits Tumor Growth through Inhibition of Tumor Cell Proliferation and Survival Signaling and by Enhancing the Host Antitumor Immune Response

J. Rosinski, H. Hilton, K. Packman, 2013 .